Apellis Pharmaceuticals Inc’s recently made public that its General Counsel Watson David O. unloaded Company’s shares for reported $0.14 million on Mar 05 ’25. In the deal valued at $25.10 per share,5,569 shares were sold. As a result of this transaction, Watson David O. now holds 138,730 shares worth roughly $3.54 million.
Then, DAVID OSBORNE WATSON bought 5,569 shares, generating $139,789 in total proceeds.
Before that, DeLong Mark Jeffrey sold 363 shares. Apellis Pharmaceuticals Inc shares valued at $10,360 were divested by the Chief Business & Strat Officer at a price of $28.54 per share. As a result of the transaction, DeLong Mark Jeffrey now holds 83,945 shares, worth roughly $2.14 million.
Goldman downgraded its Apellis Pharmaceuticals Inc [APLS] rating to a Neutral from a a Buy in a research note published recently. A number of analysts have revised their coverage, including Morgan Stanley’s analysts, who began to cover the stock in late November with a ‘”an Equal-weight”‘ rating. RBC Capital Mkts began covering APLS with “Sector perform” recommendation on October 25, 2024. William Blair started covering the stock on October 16, 2024. It rated APLS as “an Outperform”.
Price Performance Review of APLS
On Tuesday, Apellis Pharmaceuticals Inc [NASDAQ:APLS] saw its stock jump 1.51% to $25.52. Over the last five days, the stock has gained 1.88%. Apellis Pharmaceuticals Inc shares have fallen nearly -20.03% since the year began. Nevertheless, the stocks have fallen -59.13% over the past one year. While a 52-week high of $63.07 was reached on 01/07/25, a 52-week low of $23.77 was recorded on 03/04/25. SMA at 50 days reached $28.96, while 200 days put it at $33.35.
Levels Of Support And Resistance For APLS Stock
The 24-hour chart illustrates a support level at 24.95, which if violated will result in even more drops to 24.38. On the upside, there is a resistance level at 25.92. A further resistance level may holdings at 26.32. The Relative Strength Index (RSI) on the 14-day chart is 39.75, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.75, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 66.41%. Stochastics %K at 28.09% indicates the stock is a holding.
The most recent change occurred on October 16, 2024 when Scotiabank began covering the stock and recommended ‘”a Sector outperform”‘ rating .
